\
&
Contact us
\
&
Contact us
Published on | 4 years ago
Programmes Agro-Food, Environment EIC Widening/Spreading Horizon Europe HorizonEU L+FA pilot on right-to-react (or rebuttal) in the evaluation procedure of proposals was previously announced for the second/third quarter in 2021. The experts reviewing the proposals would have to take into account the input provided by the applicants during the evaluation process in the final Evaluation Summary Reports (ESR). For this pilot four calls in the Horizon Europe 2021-2022 work programme were selected:
HORIZON-EIC-2021-PATHFINDEROPEN-01
HORIZON-CL6-2022-COMMUNITIES-02
HORIZON-WIDERA-2022-TALENTS-01
A short summary of this rebuttal pilot has been made available on the NCP Flanders website on the Horizon Europe programme pages of Legal and Financial Issues, European Innovation Council (EIC), Cluster 6 and Widening Participation and Spreading Excellence and you can find the info sheet here.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
